Drug Trial Radar · NCT02531815
Dose Escalation Study of PF-06741086 In Healthy Subjects
Last checked: Nov 20, 2026Latest source record: Aug 12, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
41
Actual
Start
Aug 2015
Primary completion
Jul 2016
Study completion Jul 2016
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Aug 25, 2015
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Basic science
- Who can join
- Male only, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This Phase 1 first-in-human single ascending dose study will be a randomized, double-blind, placebo-controlled investigation of the safety, tolerability, pharmacokinetics, and pharmacodynamics of PF-06741086.
Conditions
- Healthy
Interventions
PF-06741086Biological
PF-06741086, single dose, beginning with Cohort 1 dose level at 30 mg. Subsequent dose levels will be determined after data review of prior cohort(s)
PlaceboDrug
Placebo for PF-06741086, single dose
Primary outcomes
What the sponsor says the trial is designed to measure.
- Frequency, severity and causal relationship of treatment emergent adverse events (TEAEs) and withdrawals due to TEAEsTime frame: Day 1 up to Day 84
- Percentage of subjects with laboratory abnormalitiesTime frame: Day 1 up to Day 84
- Number of subjects with change from baseline in vital signsTime frame: Day 1 up to Day 84
- Number of subjects with change from baseline in electrocardiogram (ECG) parametersTime frame: Day 1 to Day 84
- Percentage of subjects with changes from baseline in physical examinationTime frame: Day 1 to Day 84
- Percentage of subjects with infusion site reactionsTime frame: Day 1 up to Day 7
- Percentage of subjects with injection site reactionsTime frame: Day 1 to Day 7
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Pfizer Clinical Research Unit
Brussels, Belgium
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.